Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersanaâs lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersanaâs platform to advance their ADC pipelines. Source
No articles found.
Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage neuroscience company f...
Prothena Corporation plc (Nasdaq: PRTA) is a cl...
Scholar Rock is a biopharmaceutical company focused on the discovery and developme...
Scholar Rock is a biopharmaceutical company foc...
Change Healthcare is a leading independent healthcare technology company that prov...
Change Healthcare is a leading independent heal...
We are a clinical-stage biopharmaceutical company focused on developing and provid...
We are a clinical-stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.